PDCD1 and non-small cell lung carcinoma: Immune checkpoint inhibitors, including antibodies to programmed death cell death protein 1 (PD-1) and its ligand PD-L1 have revolutionized the treatment of patients with non-small cell lung cancer over the past decade.